A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Clinical trial NCT02197676 · COMPLETED

Trial details

NCT number

NCT02197676

Sponsor

Groupe Francophone des Myelodysplasies

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2014-08-04

Primary completion

2016-02-06

Enrollment

56

View on ClinicalTrials.gov